GMED
Rank #161Rank #161 by gross profitability (GP/assets 0.36) · ROE 11.4% · Piotroski F-Score 8 / 9.
As-of 2026-07-22 · CIK 0001237831 · all metrics point-in-time as of the filing date.
Financials
Weakening
Direction over 5 fiscal years
- Free cash flowimproving
- Gross margindeteriorating
- Gross profitabilitydeteriorating
- Net cashdeteriorating
- Operating margindeteriorating
- Return on equitystable
- Share count (dilution)deteriorating
Monitoring diagnostic of business direction — not a prediction of returns.
Each fiscal year is read as-of that year’s own 10-K filing, so nothing restated after the fact leaks backwards. Line items this filer never tagged are omitted. Hover or tap a badge for the diagnostic behind it.
| Fiscal year end | 2025-12-31filed 2026-02-24 | 2024-12-31filed 2025-02-20 | 2023-12-31filed 2024-02-21 | 2022-12-31filed 2023-02-21 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | 2,938.9 | 2,519.4 | 1,568.5 | 1,022.8 |
| Revenue growth (YoY) | 16.7% | 60.6% | 53.3% | 6.8% |
| Gross profit | 1,981.1 | 1,020.3 | 1,020.3 | 759.1 |
| Gross margin | 67.4% | 58.9% | 65.1% | 74.2% |
| Net income | 537.9 | 103.0 | 122.9 | 190.2 |
| Net margin | 18.3% | 4.1% | 7.8% | 18.6% |
| EPS (diluted) | $3.92 | $0.75 | $1.07 | $1.85 |
| EPS growth (YoY) | 422.7% | -29.9% | -42.2% | — |
| Cash flow | ||||
| Operating cash flow | 753.4 | 520.6 | 243.5 | 178.5 |
| Capital expenditures | 164.7 | 115.4 | 78.3 | 74.0 |
| Free cash flow | 588.8 | 405.2 | 165.2 | 104.4 |
Figures are as originally filed with the SEC (point-in-time), not restated, so they can differ slightly from sites that show later-restated numbers. Why point-in-time?